Defining a Regulatory Strategy for ATMP/Aerosol Delivery Device Combinations in the Treatment of Respiratory Disease

Abstract

Advanced Therapeutic Medicinal Products (ATMP) are a heterogenous group of investigational medicinal products at the forefront of innovative therapies with direct applicability in respiratory diseases. ATMPs include, but are not limited to, stem cells, their secretome, or extracellular vesicles, and each have shown some potential when delivered topically within the lung. This review focuses on that subset of ATMPs. One key mode of delivery that has enabling potential in ATMP validation is aerosol-mediated delivery. The selection of the most appropriate aerosol generator technology is influenced by several key factors, including formulation, patient type, patient intervention, and healthcare economics. The aerosol-mediated delivery of ATMPs has shown promise for the treatment of both chronic and acute respiratory disease in pre-clinical and clinical trials; however, in order for these ATMP device combinations to translate from the bench through to commercialization, they must meet the requirements set out by the various global regulatory bodies. In this review, we detail the potential for ATMP utility in the lungs and propose the nebulization of ATMPs as a viable route of administration in certain circumstances. Further, we provide insight to the current regulatory guidance for nascent ATMP device combination product development within the EU and US.

State of the Art Review of Cell Therapy in the Treatment of Lung Disease, and the Potential for Aerosol Delivery

“…Finally, for these therapies to become available commercially, they will need to undergo regulatory approval processes, very likely in combination with specific delivery devices for reliable and reproducible dosing. A recent review covers this area in greater detail, and discusses the likely US and EU regulatory frameworks for the ATMP/delivery device combinations [ 150 ].…”

Therapeutic Potential of Mesenchymal Stem Cells and Their Products in Lung Diseases—Intravenous Administration versus Inhalation

“…Available types of inhalers are pressurized metered dose inhalers, soft mist inhalers, dry powder inhalers and ultrasonic, jet and vibrating mesh nebulizers. Cells are sensitive to the physical and chemical stress related to formulation and aerosolization and, therefore, metered dose inhalers and dry powder inhalers are not feasible for administration [ 118 ]. However, cells can be aerosolized using soft mist inhalers, jet nebulizers and vibrating mesh nebulizers.…”

Cellular Therapy for the Treatment of Paediatric Respiratory Disease

“…Regardless of the chosen route of administration, early identification of the one to be used in the development process is key for both reasons of continuity of technology throughout the cell therapy's development and with an eye on future regulatory requirements as the therapy seeks approvals [114].…”